Analysis of High Dividend Stocks in Healthcare Sector
- High Dividend Stocks: Oramed Pharmaceuticals (ORMP) offers a dividend yield of 7.61%, making it one of the most attractive investment options in the healthcare sector for investors seeking stable income.
- Reliable Income Sources: Embecta (EMBC) and Pfizer (PFE) provide dividend yields of 6.62% and 6.36%, respectively, indicating that the healthcare sector can still deliver reliable cash flow amidst market uncertainties.
- Additional High-Yield Stocks: DENTSPLY SIRONA (XRAY) and National Research (NRC) have dividend yields of 5.02% and 4.39%, respectively, further demonstrating the investment value of the healthcare sector in the current economic climate.
- Market Focus: With oil prices exceeding $100 per barrel and geopolitical tensions, investors are showing strong interest in high-dividend stocks within the healthcare sector, reflecting a demand for stable investment opportunities.
Trade with 70% Backtested Accuracy
Analyst Views on ORMP
About ORMP
About the author
Analysis of High Dividend Stocks in Healthcare Sector
- High Dividend Stocks: Oramed Pharmaceuticals (ORMP) offers a dividend yield of 7.61%, making it one of the most attractive investment options in the healthcare sector for investors seeking stable income.
- Reliable Income Sources: Embecta (EMBC) and Pfizer (PFE) provide dividend yields of 6.62% and 6.36%, respectively, indicating that the healthcare sector can still deliver reliable cash flow amidst market uncertainties.
- Additional High-Yield Stocks: DENTSPLY SIRONA (XRAY) and National Research (NRC) have dividend yields of 5.02% and 4.39%, respectively, further demonstrating the investment value of the healthcare sector in the current economic climate.
- Market Focus: With oil prices exceeding $100 per barrel and geopolitical tensions, investors are showing strong interest in high-dividend stocks within the healthcare sector, reflecting a demand for stable investment opportunities.
Lifeward Announces 1-for-12 Reverse Stock Split
- Reverse Split Announcement: Lifeward has announced a 1-for-12 reverse stock split effective February 24, 2026, which will reduce outstanding shares from approximately 18.3 million to around 1.5 million, aimed at boosting the share price to comply with Nasdaq's $1.00 minimum bid requirement.
- Authorized Capital Increase: The board also approved increasing the authorized share capital to 100 million shares, providing greater flexibility for future financing and shareholder equity, despite the stock plummeting nearly 20% to an all-time low following the announcement.
- Historical Context: This marks Lifeward's second reverse split since March 2024, when a 1-for-7 split reduced outstanding shares from about 60.1 million to approximately 8.6 million, indicating ongoing adjustments in the company's capital management strategy.
- Partnership with Oramed: Lifeward has partnered with Oramed Pharmaceuticals to integrate its proprietary protein oral delivery technology, which could provide Lifeward with access to up to $47 million in capital, supporting future growth initiatives.
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
- Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
- Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
- Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
Oramed Pharmaceuticals Receives $18 Million Payment, Declares $0.25 Dividend
- Significant Investment Returns: Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, bringing total returns on its $99.5 million investment to $118 million, demonstrating the company's success in investment management and profitability.
- Debt Structure Optimization: Oramed retains a $27 million note and a $12 million convertible note, which can be converted into Scilex equity at $36 per share, ensuring potential capital appreciation in the future.
- Shareholder Reward Plan: The company's board approved a cash dividend of $0.25 per share, with an expected total distribution of approximately $10.5 million, aimed at rewarding shareholders and enhancing investor confidence.
- Funding Source Assurance: This dividend will be funded with surplus capital, reflecting Oramed's financial management robustness and confidence in future investments.
ORAMED PHARMACEUTICALS INC. ANNOUNCES DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS AS DIVIDEND
Rights Agreement Adoption: Oramed Pharmaceuticals has adopted a Rights Agreement to protect stockholders in the event of a hostile takeover, allowing them to purchase shares at a set price if certain ownership thresholds are met.
Details of the Rights: Each Right allows stockholders to buy one share of Common Stock at $10.00, becoming exercisable if a person or group acquires 15% or more of the company's stock, with specific terms for redemption and exchange.
Dividend Distribution: A dividend of one Right will be distributed for each outstanding share of Common Stock, payable on November 27, 2025, to stockholders of record as of that date.
Forward-Looking Statements: The press release includes forward-looking statements regarding the Rights Plan and its potential effects, emphasizing that actual results may differ due to various uncertainties.
Oramed Reports Fiscal Third Quarter 2025 Financial Results
Strong Financial Performance: Oramed Pharmaceuticals reported a net income of $65 million for the nine months ending September 30, 2025, a significant turnaround from a net loss of $6.1 million in the same period last year.
Asset Growth: The company's total assets increased by 42% year-over-year, rising from $155.3 million to $220.5 million, reflecting robust balance sheet growth.
Investment Returns: The financial improvement was largely driven by cash returns from Scilex Holding Company and unrealized gains from investments in Alpha Tau Medical Ltd. and others.
Management Insights: CEO Nadav Kidron emphasized the effectiveness of their disciplined investment strategy, which has enhanced financial flexibility and supports ongoing development of their oral drug delivery platform.
Analysis of High Dividend Stocks in Healthcare Sector
- High Dividend Stocks: Oramed Pharmaceuticals (ORMP) offers a dividend yield of 7.61%, making it one of the most attractive investment options in the healthcare sector for investors seeking stable income.
- Reliable Income Sources: Embecta (EMBC) and Pfizer (PFE) provide dividend yields of 6.62% and 6.36%, respectively, indicating that the healthcare sector can still deliver reliable cash flow amidst market uncertainties.
- Additional High-Yield Stocks: DENTSPLY SIRONA (XRAY) and National Research (NRC) have dividend yields of 5.02% and 4.39%, respectively, further demonstrating the investment value of the healthcare sector in the current economic climate.
- Market Focus: With oil prices exceeding $100 per barrel and geopolitical tensions, investors are showing strong interest in high-dividend stocks within the healthcare sector, reflecting a demand for stable investment opportunities.
Lifeward Announces 1-for-12 Reverse Stock Split
- Reverse Split Announcement: Lifeward has announced a 1-for-12 reverse stock split effective February 24, 2026, which will reduce outstanding shares from approximately 18.3 million to around 1.5 million, aimed at boosting the share price to comply with Nasdaq's $1.00 minimum bid requirement.
- Authorized Capital Increase: The board also approved increasing the authorized share capital to 100 million shares, providing greater flexibility for future financing and shareholder equity, despite the stock plummeting nearly 20% to an all-time low following the announcement.
- Historical Context: This marks Lifeward's second reverse split since March 2024, when a 1-for-7 split reduced outstanding shares from about 60.1 million to approximately 8.6 million, indicating ongoing adjustments in the company's capital management strategy.
- Partnership with Oramed: Lifeward has partnered with Oramed Pharmaceuticals to integrate its proprietary protein oral delivery technology, which could provide Lifeward with access to up to $47 million in capital, supporting future growth initiatives.
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
- Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
- Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
- Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
Oramed Pharmaceuticals Receives $18 Million Payment, Declares $0.25 Dividend
- Significant Investment Returns: Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, bringing total returns on its $99.5 million investment to $118 million, demonstrating the company's success in investment management and profitability.
- Debt Structure Optimization: Oramed retains a $27 million note and a $12 million convertible note, which can be converted into Scilex equity at $36 per share, ensuring potential capital appreciation in the future.
- Shareholder Reward Plan: The company's board approved a cash dividend of $0.25 per share, with an expected total distribution of approximately $10.5 million, aimed at rewarding shareholders and enhancing investor confidence.
- Funding Source Assurance: This dividend will be funded with surplus capital, reflecting Oramed's financial management robustness and confidence in future investments.
ORAMED PHARMACEUTICALS INC. ANNOUNCES DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS AS DIVIDEND
Rights Agreement Adoption: Oramed Pharmaceuticals has adopted a Rights Agreement to protect stockholders in the event of a hostile takeover, allowing them to purchase shares at a set price if certain ownership thresholds are met.
Details of the Rights: Each Right allows stockholders to buy one share of Common Stock at $10.00, becoming exercisable if a person or group acquires 15% or more of the company's stock, with specific terms for redemption and exchange.
Dividend Distribution: A dividend of one Right will be distributed for each outstanding share of Common Stock, payable on November 27, 2025, to stockholders of record as of that date.
Forward-Looking Statements: The press release includes forward-looking statements regarding the Rights Plan and its potential effects, emphasizing that actual results may differ due to various uncertainties.
Oramed Reports Fiscal Third Quarter 2025 Financial Results
Strong Financial Performance: Oramed Pharmaceuticals reported a net income of $65 million for the nine months ending September 30, 2025, a significant turnaround from a net loss of $6.1 million in the same period last year.
Asset Growth: The company's total assets increased by 42% year-over-year, rising from $155.3 million to $220.5 million, reflecting robust balance sheet growth.
Investment Returns: The financial improvement was largely driven by cash returns from Scilex Holding Company and unrealized gains from investments in Alpha Tau Medical Ltd. and others.
Management Insights: CEO Nadav Kidron emphasized the effectiveness of their disciplined investment strategy, which has enhanced financial flexibility and supports ongoing development of their oral drug delivery platform.
